BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32293263)

  • 1. QuaDMutNetEx: a method for detecting cancer driver genes with low mutation frequency.
    Bokhari Y; Alhareeri A; Arodz T
    BMC Bioinformatics; 2020 Mar; 21(1):122. PubMed ID: 32293263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QuaDMutEx: quadratic driver mutation explorer.
    Bokhari Y; Arodz T
    BMC Bioinformatics; 2017 Oct; 18(1):458. PubMed ID: 29065872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo discovery of mutated driver pathways in cancer.
    Vandin F; Upfal E; Raphael BJ
    Genome Res; 2012 Feb; 22(2):375-85. PubMed ID: 21653252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous identification of multiple driver pathways in cancer.
    Leiserson MD; Blokh D; Sharan R; Raphael BJ
    PLoS Comput Biol; 2013; 9(5):e1003054. PubMed ID: 23717195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovering potential cancer driver genes by an integrated network-based approach.
    Shi K; Gao L; Wang B
    Mol Biosyst; 2016 Aug; 12(9):2921-31. PubMed ID: 27426053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying overlapping mutated driver pathways by constructing gene networks in cancer.
    Wu H; Gao L; Li F; Song F; Yang X; Kasabov N
    BMC Bioinformatics; 2015; 16 Suppl 5(Suppl 5):S3. PubMed ID: 25859819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data.
    Zhang J; Zhang S; Wang Y; Zhang XS
    BMC Syst Biol; 2013; 7 Suppl 2(Suppl 2):S4. PubMed ID: 24565034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MaxCLK: discovery of cancer driver genes via maximal clique and information entropy of modules.
    Liu J; Ma F; Zhu Y; Zhang N; Kong L; Mi J; Cong H; Gao R; Wang M; Zhang Y
    Bioinformatics; 2023 Dec; 39(12):. PubMed ID: 38065693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A latent variable model for evaluating mutual exclusivity and co-occurrence between driver mutations in cancer.
    Shuaibi A; Chitra U; Raphael BJ
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of driver pathways using mutated gene network in cancer.
    Li F; Gao L; Ma X; Yang X
    Mol Biosyst; 2016 Jun; 12(7):2135-41. PubMed ID: 27118146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.
    Bányai L; Trexler M; Kerekes K; Csuka O; Patthy L
    Elife; 2021 Jan; 10():. PubMed ID: 33427197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Driver Modules with Rarely Mutated Genes in Cancers.
    Li F; Gao L; Wang B
    IEEE/ACM Trans Comput Biol Bioinform; 2020; 17(2):390-401. PubMed ID: 29994261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SSA-ME Detection of cancer driver genes using mutual exclusivity by small subnetwork analysis.
    Pulido-Tamayo S; Weytjens B; De Maeyer D; Marchal K
    Sci Rep; 2016 Nov; 6():36257. PubMed ID: 27808240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations.
    Liu S; Liu J; Xie Y; Zhai T; Hinderer EW; Stromberg AJ; Vanderford NL; Kolesar JM; Moseley HNB; Chen L; Liu C; Wang C
    Bioinformatics; 2021 Jun; 37(9):1189-1197. PubMed ID: 33165532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinguishing between driver and passenger mutations in individual cancer genomes by network enrichment analysis.
    Merid SK; Goranskaya D; Alexeyenko A
    BMC Bioinformatics; 2014 Sep; 15(1):308. PubMed ID: 25236784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of driver pathways in cancer based on combinatorial patterns of somatic gene mutations.
    Li HT; Zhang J; Xia J; Zheng CH
    Neoplasma; 2016; 63(1):57-63. PubMed ID: 26639234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of constrained cancer driver genes based on mutation timing.
    Sakoparnig T; Fried P; Beerenwinkel N
    PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways.
    Wang X; Kostrzewa C; Reiner A; Shen R; Begg C
    Am J Hum Genet; 2024 Feb; 111(2):227-241. PubMed ID: 38232729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OMEN: network-based driver gene identification using mutual exclusivity.
    Van Daele D; Weytjens B; De Raedt L; Marchal K
    Bioinformatics; 2022 Jun; 38(12):3245-3251. PubMed ID: 35552634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer.
    Narayan S; Bader GD; Reimand J
    Genome Med; 2016 May; 8(1):55. PubMed ID: 27175787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.